Investigational Drug Information for pyrotinib
✉ Email this page to a colleague
What is the drug development status for pyrotinib?
pyrotinib is an investigational drug.
There have been 132 clinical trials for pyrotinib.
The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2021.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, and Lung Neoplasms. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Fudan University, and Sun Yat-sen University.
There are six US patents protecting this investigational drug and ninety international patents.
Summary for pyrotinib
| US Patents | 6 |
| International Patents | 90 |
| US Patent Applications | 30 |
| WIPO Patent Applications | 13 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 1 (2021-07-01) |
| Vendors | 30 |
Recent Clinical Trials for pyrotinib
| Title | Sponsor | Phase |
|---|---|---|
| Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer | Fudan University | Phase 2 |
| Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer | RenJi Hospital | Phase 3 |
| Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer | Fudan University | Phase 3 |
Clinical Trial Summary for pyrotinib
Top disease conditions for pyrotinib
Top clinical trial sponsors for pyrotinib
US Patents for pyrotinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Pyrotinib | ⤷ Try a Trial | Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof | Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, Jiangsu, CN) | ⤷ Try a Trial |
| Pyrotinib | ⤷ Try a Trial | Method for preparing tyrosine kinase inhibitor and derivative thereof | Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, Jiangsu, CN) | ⤷ Try a Trial |
| Pyrotinib | ⤷ Try a Trial | Method for preventing or treating tumor diseases with a combination of tyrosine kinase inhibitor and CDK4/6 inhibitor | JIANGSU HENGRUI MEDICINE CO., LTD. (Jiangsu, CN) SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (Shanghai, CN) | ⤷ Try a Trial |
| Pyrotinib | ⤷ Try a Trial | 6-amino quinazoline or 3-cyano quinoline derivatives, preparation methods and pharmaceutical uses thereof | Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, Jiangsu, CN) Shanghai Hengrui Pharmaceutical Co., Ltd. (Shanghai, CN) | ⤷ Try a Trial |
| Pyrotinib | ⤷ Try a Trial | Crystalline form I of tyrosine kinase inhibitor dimaleate and preparation methods thereof | Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, Jiangsu, CN) | ⤷ Try a Trial |
| Pyrotinib | ⤷ Try a Trial | Pharmaceutical uses of 6-amino quinazoline or 3-cyano quinoline derivatives | Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, Jiangsu, CN) Shanghai Hengrui Pharmaceutical Co., Ltd. (Shanghai, CN) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for pyrotinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Pyrotinib | Australia | AU2017211737 | 2036-01-27 | ⤷ Try a Trial |
| Pyrotinib | Brazil | BR112018014544 | 2036-01-27 | ⤷ Try a Trial |
| Pyrotinib | Canada | CA3008701 | 2036-01-27 | ⤷ Try a Trial |
| Pyrotinib | China | CN107405345 | 2036-01-27 | ⤷ Try a Trial |
| Pyrotinib | China | CN108938586 | 2036-01-27 | ⤷ Try a Trial |
| Pyrotinib | Denmark | DK3378479 | 2036-01-27 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
